European Journal of Heart Failure (2014) 16, 810–816 doi:10.1002/ejhf.114
Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT Michel Komajda1*, Michael Böhm2, Jeffrey S Borer3, Ian Ford4, Michele Robertson4, Athanasios J. Manolis5, Luigi Tavazzi6, and Karl Swedberg7, on behalf of the SHIFT Investigators 1 Institute
of Cardiometabolism and Nutrition (ICAN), Pierre et Marie Curie Paris VI University, La Pitié-Salpétrière Hospital, Paris, France; 2 Universitätskliniken des Saarlandes, Klinik für Innere Medizin III, Homburg/Saar, Germany; 3 Division of Cardiovascular Medicine and the Howard Gilman Institute for Heart Valve Disease and the Schiavone Institute for Cardiovascular Translational Research, State University of New York Downstate Medical Center, New York, NY, USA; 4 Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK; 5 Asklepeion Hospital, Athens, Greece; 6 Maria Cecilia Hospital, GVM Care and Research, Ettore Sansavini Health Science Foundation, Cotignola, Italy; and 7 Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden Received 27 January 2014; revised 31 March 2014; accepted 4 April 2014 ; online publish-ahead-of-print 24 June 2014
Aims
Low systolic blood pressure (SBP) is associated with poor outcomes in heart failure and complicates management. In a post hoc analysis, we investigated the efficacy and safety of ivabradine in the SHIFT population divided by tertiles of baseline SBP. ..................................................................................................................................................................... Methods The analysis comprised 2110 patients with SBP
Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT Michel Komajda1*, Michael Böhm2, Jeffrey S Borer3, Ian Ford4, Michele Robertson4, Athanasios J. Manolis5, Luigi Tavazzi6, and Karl Swedberg7, on behalf of the SHIFT Investigators 1 Institute
of Cardiometabolism and Nutrition (ICAN), Pierre et Marie Curie Paris VI University, La Pitié-Salpétrière Hospital, Paris, France; 2 Universitätskliniken des Saarlandes, Klinik für Innere Medizin III, Homburg/Saar, Germany; 3 Division of Cardiovascular Medicine and the Howard Gilman Institute for Heart Valve Disease and the Schiavone Institute for Cardiovascular Translational Research, State University of New York Downstate Medical Center, New York, NY, USA; 4 Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK; 5 Asklepeion Hospital, Athens, Greece; 6 Maria Cecilia Hospital, GVM Care and Research, Ettore Sansavini Health Science Foundation, Cotignola, Italy; and 7 Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden Received 27 January 2014; revised 31 March 2014; accepted 4 April 2014 ; online publish-ahead-of-print 24 June 2014
Aims
Low systolic blood pressure (SBP) is associated with poor outcomes in heart failure and complicates management. In a post hoc analysis, we investigated the efficacy and safety of ivabradine in the SHIFT population divided by tertiles of baseline SBP. ..................................................................................................................................................................... Methods The analysis comprised 2110 patients with SBP
